v2.4.0.6
Condensed Consolidated and Combined Income Statements (Unaudited) (USD $)
In Millions, except Share data in Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Income Statement [Abstract]        
Revenue $ 931 $ 939 $ 2,822 $ 2,800
Cost of revenue 557 574 1,702 1,719
Gross profit 374 365 1,120 1,081
Selling, general and administrative expenses 231 215 682 643
Research and development expenses 24 23 80 73
Restructuring and asset impairment charges, net 4 2 4 2
Separation costs 4 46 15 67
Operating income 111 79 339 296
Interest expense 14 1 41 2
Other non-operating income, net 3 4 1 5
Income before taxes 100 82 299 299
Income tax expense 28 5 75 72
Net income $ 72 $ 77 $ 224 $ 227
Earnings per share:        
Basic $ 0.39 $ 0.42 [1] $ 1.20 $ 1.23 [1]
Diluted $ 0.38 $ 0.42 [1] $ 1.20 $ 1.23 [1]
Weighted average number of shares:        
Basic 185,931 184,570 [1] 185,726 184,570 [1]
Diluted 186,348 184,570 [1] 186,152 184,570 [1]
Dividends declared per share $ 0.1012 $ 0 $ 0.3036 $ 0
[1] Basic and diluted earnings per share for all periods prior to the Spin-off reflect the number of distributed shares on the Distribution Date, or 184.6 million shares. At the time of the Spin-off, ITT stock options and restricted stock awards were converted to awards of Xylem, and therefore there were no dilutive securities outstanding for the period prior to Spin-off.